UNSPSC 51294211: Reboxetine mesilate or mesylate

This classification denotes an antidepressant agent with the molecular formula C19H23NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L94J81YNNY, chemically known as (+/-)-(r*,s*)-2-((2-ethoxyphenoxy)phenylmethyl)morpholine methanesulfonate, but more generally known as reboxetine mesylate, which bears US NIH Compound Identifier 127150. European Medicines Agency schedules reboxetine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15112MIG.

Most nations, for tariff purposes, schedule reboxetine mesylate under HS 29349990. As of Q4 2014, REBOXETINE MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC1CCCCC1O[C@H](C2CCCCC2)[C@H]3CNCCO3.CS(=O)(=O)O.

UNSPSC 51294211 Reboxetine mesilate or mesylate is a Commodity code that nominally covers a specific antidepressant pharmaceutical. Recent state and local procurement activity under this code shows a mismatch: the single identified opportunity involves procurement of naloxone (an opioid antagonist) and drug deactivation systems for community health support, not reboxetine. State and local governments soliciting under this code are primarily county-level health and community services bodies focused on emergency response and public health initiatives. The work being bought is the supply and quarterly delivery of pharmaceutical products and related systems to support overdose response and substance-use harm reduction programs.

Seminole County, Florida posted the sole recent opportunity under this code—IFB 60459723LAS, released June 30, 2026, with a response deadline of July 26, 2023 (note: date discrepancy in source). The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford. The IFB required electronic bid submission through the county's e-procurement portal, included all shipping and delivery costs in pricing, and carried a two-year initial term with one-year renewal option. Vendors faced standard compliance requirements including drug-free workplace certification, E-Verify participation, and specified insurance coverages. The contract included potential FEMA funding with associated federal environmental and oversight requirements. The code shows limited recent state and local activity; procurement under this specific pharmaceutical commodity is not a frequent or widespread state and local practice.